Any idea why this is dropping like a rock over the last couple of weeks? Just curious if anyone say some news about the company I'm not aware of?

Still a few years away from really benefitting from this stock. I've held it a long time and seen it go down a good bit but I keep it because I know the attitudes and laws will eventually change. There is already a movement by the younger generation to change the government but it will still take several more years. Once that happens, companies like this will thrive as they are already established and in a good position to maximize.

I rarely invest long term but this is one exception. I feel it's at a bargain price at the moment. Will probably stay that way for quite a while but as the movement in Australia changes I slowly load up and wait.

ACNNF—Strong move on low volume—

JMO—More to come—GLTA!

Going to keep this one on my radar. 2 years on cash on hand no debt, TGA looks to be moving forward. Clearly still in R&D / Clinical phase but making what I see as normal progression towards commercialization.

Certainly TGAs rulings will play a major role here, it’s a bet on TGA and the clinical validation to hold true. Basically like a bet on a ore market drug company.

Chart been more or less bottomed out for awhile. So maybe I pick up a few shares, planning to hold for a few years though. This will absolutely not be a momo play, potentially be awhile (1-3 yrs so be prepared for that)

And the progress keeps on progressing!!!
Enjoy!

https://clients3.weblink.com.au/pdf/AC8/02228764.pdf

JAX

News is out come and get!!! $$$$&

https://clients3.weblink.com.au/pdf/AC8/02226239.pdf

JAX

https://www.examiner.com.au/story/6669304/auscann-cashed-up-for-medicinal-cannabis-progress/

Can someone please verify?
Thanks!

JAX

https://clients3.weblink.com.au/pdf/AC8/02213191.pdf

I believe this is our guy?

https://hunterpainspecialists.com.au/news

Losertrying2win!

Can you please sticky the latest news release?

AusCann releases low-dose form capsule to enable customised dosing solutions

We’re in business $$$$$

https://www.asx.com.au/asxpdf/20200218/pdf/44f5mvl1kg0wbj.pdf

JAX

I scooped up another 5k shares :) patients is a virtue.

JAX

AusCann accelerates path towards commercialisation with capsules released for clinical evaluation in December Quarter

Highlights

Completed development of hard shell capsule ready for the next phase of clinical evaluation and commercialisation.
Completed construction of AusCann’s product development facility.
Board renewal process finalised.
30 January 2020 – Medicinal cannabis pharmaceutical company AusCann Group Holdings Limited (ASX: AC8) (‘AusCann’ or ‘the Company’) is pleased to provide an overview of its activities for the three months ended 31 December 2019.

AusCann had a cash balance at the end of the quarter of circa $26m. Net cash outflows for the quarter were $6.405m due primarily to construction costs of $3.426m in respect to the product development facility, and operational costs of $2.871m including R&D costs of $0.979m. AusCann expects cash outflows next quarter of approximately $4.678m.

The Company remains well funded to reach its key milestones and will focus its capital on its core R&D program including clinical evaluation, product manufacturing and commercialisation.

Hard Shell Capsules Released for Clinical Evaluation

AusCann reached a major milestone during the quarter announcing on 18 December 2019 finalising the successful development, manufacturing and testing of its proprietary cannabinoid-based hard-shell capsules.

Testing of the capsules was completed according to standardised validated tests used across the pharmaceutical industry to ensure product quality, dose reliability and consistent performance through the shelf life of the product.

The Company is working to develop a commercially focused, short clinical evaluation. AusCann's solid fill capsule formulation is a unique presentation for cannabinoid medicines, and the clinical evaluation goal is to provide key exposure information to inform dose selection, bioavailability and safety.

AusCann is targeting to have the hard-shell capsules commercially available for physicians to prescribe in Australia through the Therapeutic Good Administration (TGA) special access scheme and authorised prescriber scheme during the first half of CY 2020.

The capsule is manufactured by PCI Pharma and a three-year agreement was executed with TGA licensed Aspen Pharmacare Australia (Aspen) to provide cost-efficient packaging of the capsules in consumer-ready packs at its Australian facility.

Product Development Site

During the quarter AusCann completed the next stage of its facility based in Perth, Western Australia. The site construction was completed on time and on budget with $4.5m spent to date and additional capital spend to be deployed within the original $6m budget the company announced on 25 January 2019. The site provides AusCann with a state of the art R&D facility that will assist in the development of innovative cannabinoid-based medicines pipeline.

The Company has recently moved its administration headquarters to the new facility.

Change in Substantial Shareholder

During the quarter long term investor Merchant Funds Management Pty Ltd acquired a 13.2% interest in AusCann from Canopy Growth Corporation. Merchant is a financial services firm with extensive experience in the medical cannabis sector.

Board Renewal Process Completed

The Board renewal process was completed in December with the appointment of Mr Max Johnston as a Non-Executive Director of AusCann on 19 December 2019 and Chairman of the Company effective 19 January 2020.

Ms Krista Bates was appointed as a Non-Executive on 20 December 2019 and brings over 18 years of legal expertise to the Board, and Mr Chris Mews was appointed as Merchant’s Board nominee on 1 December 2019.

AusCann CEO, Mr Ido Kanyon said the last few months were pivotal for AusCann with the completion of preclinical product development, commercial manufacturing and release of the Company’s hard-shell capsules for clinical evaluation.

“The team at AusCann had been working relentlessly towards this milestone with manufacturing and testing successfully completed and meeting the strictest pharmaceutical quality and conformance standards. Finding the right packaging partner was also of critical importance. AusCann has signed a three-year agreement with leading global pharmaceutical packaging company Aspen.

“There is a lack of quality clinical evidence for medicinal cannabis pharmaceuticals in the industry and that is why we are generating the evidence to demonstrate the uniqueness and consistency of our capsules while building medical acceptance with Australian-based physicians.

“This is an exciting time for AusCann as we establish the Company as a trusted pharmaceutical player with a reliable, stable and standardised product. We are committed to making our capsules commercially available for prescription to patients in Australia during the first half of 2020.”

ENDS

This ASX announcement was authorised for release by the Board of AusCann.

been a long wait here but i think the worm is turning now!!--hope the pps chase gets us up fast soon----tmonkey

2020 is going to be a big year here.

AusCann on a high with cannabis capsule release

Shares in WA medical cannabis company AusCann have skyrocketed on the release of its cannabinoid-based hard-shell capsules for clinical evaluation.

AusCann chief executive Ido Kanyon said the successful manufacture, testing and release of a commercial-sized batch of the capsules marked a critical milestone for the company.

Cannabinoids tend to degrade over time when not protected but AusCann said its capsules, which have now passed Australian Therapeutic Goods Administration standards, are designed to perform consistently throughout the shelf life of the product.

AusCann shares were up 9.5¢, or 52.8 per cent, to 27.5¢ at 11.45am.

Mr Kanyon said he hoped to make the capsules available for physicians to prescribe in Australia during the first half of next year.

“Now with this stage of our R&D program complete, we are accelerating our path toward commercialisation with full confidence in our ability to consistently provide reliable, stable and standardised pharmaceutical products which address unmet medical needs,” he said.

The news comes just months after the arrival of activist shareholder Merchant Group heralded a shake-up of AusCann’s board that included the departure of founder and chairman Mal Washer.

Former Liberal MP Dr Washer stepped down from the board in October and was replaced as chairman by non-executive director Cheryl Edwardes, who will also leave early next year.

Merchant bought out Canada’s Canopy Growth last month to become AusCann’s biggest shareholder with a 12.4 per cent stake.

Merchant, which drove the revival of medical cannabis company HAPA Pharm, is believed to have argued board changes were necessary if AusCann was to regain its momentum and capitalise on its initial promise as one of Australia’s first cannabis companies.

https://thewest.com.au/business/health/auscann-on-a-high-with-cannabis-capsule-release-ng-b881414901z

Why did the AusCann share price rocket higher today?

Investors have been buying AusCann’s shares following the release of an update in relation to its proprietary cannabinoid-based hardshell capsules.

According to the release, AusCann has completed manufacturing and testing of the hard-shell capsules and released the hard-shell capsules for clinical evaluation. Management advised that the clinical evaluation goal is to provide key exposure information to inform dose selection.

The release explains that its testing was conducted in accordance to standardised validated tests used across the pharmaceutical industry. This is to ensure product quality prior to release of products to market.

The hard-shell capsules were tested and found to meet all applicable pre-defined criteria set by the Australian Therapeutic Goods Administration, relevant International Pharmacopoeial standards, and the company’s own quality assurance and control procedures.

AusCann is now targeting hard-shell capsules availability for patients in Australia during the first half of calendar year 2020.

AusCann CEO, Mr Ido Kanyon, was pleased with the development.

He said: “AusCann had the vision to provide patients and healthcare professionals with a high quality pharmaceutical product which addresses patients’ unmet needs. AusCann’s manufacturing, operational processes and test results are up to global pharmaceutical standards which is great news for patients, healthcare professionals and AusCann’s investors.”

“Now with this stage of our R&D program complete, we are accelerating our path toward commercialisation with full confidence in our ability to consistently provide reliable, stable and standardised pharmaceutical products which address unmet medical needs.”

“We remain focused on making AusCann’s capsules available for prescription to patients in Australia during the first half of 2020. Our goal is to provide high-quality medicine and to obtain detailed, data-driven evaluations regarding the outcomes of AusCann’s pharmaceutical treatment. These results will build the clinical evidence supporting the unique benefits of AusCann’s capsules necessary to open a large market for the Company,” he concluded.

The post Why this ASX cannabis share rocketed 35% higher today appeared first on Motley Fool Australia.

https://au.finance.yahoo.com/news/why-asx-cannabis-share-rocketed-003043523.html

Annual General Meeting

Ido Kanyon – Chief Executive Officer 29 November 2019

https://clients3.weblink.com.au/pdf/AC8/02179565.pdf

It's done, not much else to say the outlook is not good anymore

There making this dip because they are loading and if you have held your shares for over 1year only 15% tax .. But if you panic and sell then buy back in at a lower price then you will be taxed 37%.
Do the math.. The whole sector is down and normally sector will light up like a Christmas tree in Dec.to January.. New lows go to new highs...
I know end of 2019 Auscann will report on there trials..so im expecting news in Dec..

For now ..i am loading the boat... 5 shares for less than a buck... But when it hits 1$ thats 5 times my investment... Very good position to load as to what your seeing now...

Last week someone wanted 38,800 shares @.173
How did that go for ya... It didnt...

Lots of ppl on these boards try to scare ppl off and get there fill cheap.. Dont fall victim to the games.. Know what you own .. And this is just my opinion...

If people are looking for one that will soon Fly..
Look at BioAmber Inc.. BI0@q.. GLTA

Yep :)

JAX

If they bought the ask we would be at .24 in 10k shares... Someone is trying to load at .173 and sell at .25.. Thats whats going on here.. Then walk back down to reload..

It really cracks me up how ppl talk all doom and gloom yet someone wants 38,000 shares @ .173

And the ask is at .201. Someone will really be in the green if they sell at .173..

Don't let these people scare you out of a great investment..

https://ibb.co/BTcH8dW

It really cracks me up how ppl talk all doom and gloom yet someone wants 38,000 shares @ .173

And the ask is at .201. Someone will really be in the green if they sell at .173..

Don't let these people scare you out of a great investment..

https://ibb.co/BTcH8dW

Sorry.. I am in the watch and load department..end of 2019 they will pr there trial results and wala.. We climb ny year end.

Canopy was an important partner, which is why I bailed, even at such a low price.

Auscann Holding will be alright .. Some other company bought 11.43% or 36.2 mill shares.. Ppl here just want your shares cheap.. I will keep
loadi ng ...Not shook one bit

.15 Aussie = .10 US I think. Not good!

CGC just dumped on a 50% discount..wow

Canopy Growth divests AusCann stake
Oct. 13, 2019 6:58 PM ET

https://seekingalpha.com/news/3505405-canopy-growth-divests-auscann-stake

Mutual Fund buys 36.2M shares
https://www.asx.com.au/asxpdf/20191011/pdf/449f0gd0wk73q3.pdf

https://www.ganjapreneur.com/australian-government-investing-3m-for-medical-cannabis-studies/

Q&A on Sept 25th see post below!

https://clients3.weblink.com.au/pdf/AC8/02146037.pdf

JAX

Rock & Roll time children!$
https://clients3.weblink.com.au/pdf/AC8/02143641.pdf

Resume:
https://csts.mst.edu/media/research/csts/images/newsandevents/CSTS_Bonn-Miller%20Curriculum%20Vitae.pdf

JAX

AusCann Group Holdings Limited

AusCann Group Holdings Limited (ASX: AC8) is in the business of medicinal cannabis product cultivation, manufacturing and delivery. The company is also involved in distribution activities across Australia through established pharmaceutical distribution channels as well as unregistered product pathways.

Recent Updates:

The company, on 23 July 2019, issued 50,000 fully paid ordinary shares at $ 0.21 per share on exercise of 50,000 unlisted options, scheduled for expiry on 19 January 2020.
On 01 July 2019, AC8 notified the market about signing an agreement with Tasmanian Alkaloids (TasAlk). Under the deal, AusCann will secure high-quality cannabis raw material from TasAlk. The company will use the material for cannabinoids-based pharmaceuticals development and production. The strategic alliance between the two was undertaken in 2017 to benefit from each other’s abilities with regards to cannabis plant cultivation along with manufacturing and marketing of cannabis products.
On 8 March 2019, S&P Dow Jones Indices announced the March 2019 quarterly rebalance of the S&P/ASX Indices. The company was added to All Ordinaries, effective at the open on 18 March 2019.

March Quarter 2019 Updates: The company appointed Mr. Ido Kanyon as new Chief Executive Officer during the period. Further, AC8 inked an agreement for purchasing cannabis resin from MediPharm Labs, which is the largest supplier of purified, pharmaceutical grade cannabis extracts in Canada.

The company bought a R&D (Research & Development) facility of 7,300 square metres to further improve its product development capabilities. The facility is based in Perth, the capital city of Western Australia. The consideration price for the facility was $ 5.25 million, which was fully funded from existing cash reserves on the balance sheet and the anticipated completion of the facility is CY 2019.

1H FY19 Results Review (ended 31 December 2018): The company, in July 2018, accomplished a share placement program and raised A$ 33.5 million. An amount of A$ 1.9 million was further raised in August 2018 through a share purchase plan. AC8 posted a loss of $ 4,438,372 in 1HFY19 as compared to $ 4,829,822 in the prior corresponding period. On balance sheet, net assets rose to $ 43,255,881 at the end of 1H FY19 from $ 14,112,032 at 30 June 2018. Total current liabilities at the end of the period stood at $ 592,819, slightly lower as compared to $ 600,139 at the end of June 2018. Accumulated losses at the end of 1H FY19 were $ 31,810,379 as compared to $ 27,372,007 at the end of 1H FY18.

1H19 Results Highlights (Source: Company Reports)

Key Focus Areas for FY2019: The company intends to launch solid hard-shell capsules to treat chronic pain which is likely to be released for clinical trials in 2019. The company plans to continue with diversifying and boosting cannabis raw material supply base. With regards to the product development, the company is progressing towards the development of a new AusCann R&D facility in Western Australia. The facility will be engaged in cultivation, extraction and new product development activities. AC8 is likely to invest a further capital of ~$ 6 million in the upcoming time for the customisation of the site.

AC8 stock was trading at $ 0.510 on 29 July 2019 (AEST 02:41 PM), up 7.368% from its previous closing price. The company has a market cap of $ 150.57 million and 317 million outstanding shares. The stock gave a negative return of 26.36% in the past six months.

Here we go. This is what we have been waiting for!

I stand corrected, I was using $1.50. Having said, Auscann seems to be waking up under the new CEO.

Actually, our price is a fairly accurate U.S. equivalent. Aussie$ is 1.45 to U.S.$ 1. So multiply our price by 1.45 or divide Aussie price by 1.45 and they should be just about the same.

MM's are criminals, stock closed in Australia @.48!

I Concur :)

JAX

Action lately suggests that something positive is happening

Zelda I believe is the son of the founder of AusCann.

https://www.9news.com.au/national/medical-cannabis-clinics-emerald-zelda-therapeutics-health-news-australia/c590221d-914d-4e54-8225-42e545815785

JAX

I believe you to be correct, especially since the son just go approval to produce their capsules and are already in several burgeoning cannabis clinics. son like father on this one. Lol. I’m sure we won’t be to far behind :) you can see it!

JAX

This one is just a matter of time.

Up 19% today!!!! Ring it hard and ring it loud$$$ bring it! Our little engine:)

JAX

I’m ready baby!!! I hope this is the start of something big.

https://www.9news.com.au/national/medical-cannabis-clinics-emerald-zelda-therapeutics-health-news-australia/c590221d-914d-4e54-8225-42e545815785

JAX

hope our long wait is over!!-the us ticker tail will be wagged big time by the aussie dog today!!.-------tmonkey

Rumble, rumble down Under :)

JAX

Nice!!! Tonight is rocking down under :)

JAX

Looking good here..Longs will be rewarded IMO